Commentary
The authors of this study aimed to quantify the proportion of participants with a valid follow-up biopsy in randomised clinical trials in NASH with at least 1-year follow-up. Forty-one trials were included. The proportion of participants with a valid follow-up biopsy was 82%, without evidence of a difference by location, trial length, or by allocated treatment group. Biopsy-related serious adverse events occurred in 16 per 1,000 participants, without biopsy-related deaths. These findings can inform adequately-powered trials.
